Genmab — Juni 2025

[JKY_VH]

Super og mange tak for den Budweis:-)

[Bulder]

Epco fortsætter sin sejrsgang. Det bliver stort - ad åre.

[E_L]

Lymphoma Hub
@lymphomahub
CONGRESS | #EHA2025 | PRESENTATION
Daniel Kerr,
@TGHCares presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5
trial (N = 37). https://x.com/lymphomahub/status/1934185493723263388

[E_L]

"These promising results compare favorably to other regimens in 1L and may provide higher cure rates for patients with 1L DLBCL than SOC", suggesting that further exploration is warranted.

[Helge_LarsenPI-redaktør]

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) https://proinvestor.com/investornyt/1329270/genmab-announces-epcoritamab-investigational-combination-therapy-demonstrates-high-response-rates-in-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-eligible-for-autologous-stem-cell-trans

[Solsen]

[Solsen]

https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html Flotte resultater på Genmab bispecific vi ser i NHL og MM. Specielt imponerede med epco i first line kombo.

[E_L]

Investigational combination of first-in-class bispecifics TALVEY and TECVAYLI shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease https://finance.yahoo.com/news/investigational-combination-first-class-bispecifics-071500581.html

[E_L]

sry that's the same one lol

[E_L]

Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL https://www.onclive.com/view/fixed-duration-epcoritamab-plus-pola-r-chp-demonstrates-durable-efficacy-in-first-line-dlbcl

[ProinvestorNEWS]

Genmab har lovende resultater med kræftmiddel i lymfekræftform https://proinvestor.com/investornyt/1329375/genmab-har-lovende-resultater-med-kraeftmiddel-i-lymfekraeftform

[gentogen]

"Lovende" er da vist en underdrivelse...

[Raun]

Ja enig - det er jo vildt imponerende

[wisuwa]

Nå... Har været lidt fraværende i Genmab-regi. Hvad ser vi ind i nu? Hvad er kurstriggerne? Og nogle der har regnet på et
EOY kursniveau?

[Helge_LarsenPI-redaktør]

Transactions in Connection with Share Buy-back Program https://proinvestor.com/investornyt/1329527/transactions-in-connection-with-share-buy-back-program

[E_L]

EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial https://finance.yahoo.com/news/eha-2025-genmab-abbvie-epkinly-134631049.html

[ProinvestorNEWS]

Hej wisuwa...Du kan evt starte med at læse chathistorikken. https://proinvestor.com/chathistory/-25/genmab

[ProinvestorNEWS]

Jyske Bank: Genmab – Positivt nyt fra Epcoritamab https://proinvestor.com/investornyt/1329914/jyske-bank-genmab-positivt-nyt-fra-epcoritamab

[E_L]

España lidera un estudio pionero con epcoritamab para mejorar el abordaje del linfoma B de células grandes https://www.immedicohospitalario.es/noticia/51673/espana-lidera-un-estudio-pionero-con-epcoritamab-para-mejorar-el-abor.html REPIFIR = Response-adaptive to Epcoritamab In FIrst Relapse

[bikube]

UHA, det bliver sjovt at evaluere på. Men den enkelte patients behov må jo komme i første række.